Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CA19-9 monoclonal antibody BNT321

A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the carbohydrate antigen sialyl Lewis A (carbohydrate antigen 19-9; CA19-9), with potential antineoplastic activity. Upon administration, anti-CA19-9 monoclonal antibody BNT321 targets and binds to CA19-9, and kills CA19-9-expressing tumor cells through the induction of both complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). CA19-9 is overexpressed on a number of different tumor cell types, and plays a key role in tumor cell survival and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CA19-9 monoclonal antibody 5B1
HuMab 5B1
HuMab-5B1
Code name:5B1
BNT 321
BNT-321
BNT321
MVT-5873
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search